Optimal duration of dual antiplatelet therapy after stent-assisted coil embolization of unruptured intracranial aneurysms: A prospective randomized multicenter trial

Seung Pil Ban,1,2 O-Ki Kwon,1,2 Young Deok Kim,1,2 Bum-Tae Kim,3 Jae Sang Oh,4 Kang Min Kim,2,5 Chang Hyeun Kim,6 Chang-Hyun Kim,7 Jai Ho Choi,8 Young Woo Kim,9 Yong Cheol Lim,10 Hyoung Soo Byoun,11 Sukh Que Park,12 Joonho Chung,13 Keun Young Park,13 Jung Cheol Park,14 Hyon-Jo Kwon,15 Korean NeuroEndovascular Society

1Departments of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea
2Departments of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea
3Departments of Neurosurgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
4Departments of Neurosurgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea
5Departments of Neurosurgery, Seoul National University Hospital, Seoul, Korea
6Departments of Neurosurgery, Pusan National University Yangsan Hospital, Yangsan, Korea
7Departments of Neurosurgery, Keimyung University Dongsan Medical Center, Daegu, Korea
8Departments of Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
9Departments of Neurosurgery, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Uijeongbu, Korea
10Departments of Neurosurgery, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea
**Running title:** Optimal duration of dual antiplatelet therapy

• Received : April 17, 2022 • Revised : June 5, 2022 • Accepted : June 14, 2022

**Co-corresponding author:** O-Ki Kwon

Department of Neurosurgery, Seoul National University Bundang Hospital, 82 Gumi-ro 173 beon-gil, Bundang-gu, Seongnam 13620, Korea

Tel : +82-31-787-7163, Fax : +82-31-787-4097, E-mail : neurokwonoki@gmail.com, ORCID : https://orcid.org/0000-0002-7379-9891

**Joonho Chung**

Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Abstract

Objective: Stent-assisted coil embolization (SAC) has been increasingly used to treat various types of intracranial aneurysms. Delayed thromboembolic complications are major concerns regarding this procedure, so dual antiplatelet therapy with aspirin and clopidogrel is needed. However, clinicians vary the duration of dual antiplatelet therapy after SAC, and no randomized study has been performed. This study aims to compare the safety and efficacy of long-term (12 months) dual antiplatelet therapy and short-term dual antiplatelet therapy (6 months) after SAC for patients with unruptured intracranial aneurysms (UIAs).

Methods: This is a prospective, randomized and multicenter trial to investigate the optimal duration of dual antiplatelet therapy after SAC in patients with UIAs. Subjects will receive dual antiplatelet therapy for 6 months (short-term group) or 12 months (long-term group) after SAC. The primary endpoint is the assessment of thromboembolic complications between 1 and 18 months after SAC. We will enroll 528 subjects (264 subjects in each group) and perform 1:1 randomization. This study will involve 14 top-performing, high-volume Korean institutions specializing in coil embolization.

Results: The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up.

Conclusion: This article describes that the aim of this prospective randomized multicenter trial is to compare the effect of short-term (6 months) and long-term (12 months) dual antiplatelet therapy on UIAs in patients undergoing SAC, and to find the optimal duration.

Key Words: Endovascular procedures · intracranial aneurysm · dual anti-platelet therapy · stent · thromboembolism.
INTRODUCTION

The recent introduction of stents has led to the increased use of stent-assisted coil embolization (SAC) for various types of intracranial aneurysms. Deploying the stent across the aneurysmal neck creates a mechanical barrier to prevent coil protrusion into the parent artery and helps to achieve compact coil packing. In addition, stent placement can reduce the recanalization rates by inducing stable thrombosis within the aneurysmal sac, modulating hemodynamic factors and improving neo-endothelialization. However, because of the thrombogenicity of stents, thromboembolic complications are major concerns for patients undergoing this procedure, so periprocedural dual antiplatelet therapy with aspirin and clopidogrel is necessary to eradicate these concerns. Gradually, over time, thrombogenicity decreases because of intrinsic fibrinolytic activity of the endothelium and neo-endothelium covering the stent surface. Accordingly, most clinicians perform dual antiplatelet therapy within 6 months after SAC and switch to mono antiplatelet therapy (daily aspirin) to avoid the risks associated with dual antiplatelet therapy.

Although Matsumoto et al. reported that thromboembolic events after the procedure are most likely to occur within 40 days after SAC even if patients receive dual antiplatelet therapy, previous studies reported that delayed thromboembolic complications can occur after 40 days. These studies commonly found that an insufficient duration of dual antiplatelet therapy was associated with delayed thromboembolic events, which indicates the need for an extended duration of dual antiplatelet therapy. On the other hand, another study showed that long-term use of dual antiplatelet therapy after SAC increased the frequency of delayed hemorrhagic events. Clinicians varied the duration of dual antiplatelet therapy after SAC, which was consistent with similar studies. The currently used antiplatelet therapy protocol for SAC is based on the guidelines for coronary intervention. However, since cerebral aneurysm is anatomically and pathologically different from cardiovascular diseases, it is unclear whether the antiplatelet therapy protocol used for coronary intervention is safe or effective in patients undergoing SAC for unruptured intracranial aneurysms (UIAs). In addition, no randomized
study regarding neuroendovascular treatment has been performed to address this issue.

Therefore, the aim of this study is to assess the effect and safety of long-term (12 months) dual antiplatelet therapy in patients with UIAs after undergoing SAC by evaluating the occurrence of delayed thromboembolic and hemorrhagic events compared with the short-term (6 months) dual antiplatelet therapy.

**MATERIALS AND METHODS**

**Design**

This is a prospective, multicenter (14 institutions), randomized, controlled trial designed that aims to compare the effect and safety of long-term (12 months) dual antiplatelet therapy with short-term (6 months) dual antiplatelet therapy in patients with UIAs after undergoing SAC. Participants will be randomly assigned, 1:1, to a short-term duration group or a long-term duration group. The study flowchart is shown in Fig. 1.

**Study population**

The study population will enroll 528 subjects with UIAs, who are age ≥ 19 years and eligible for SAC (as confirmed by digital subtraction angiography [DSA]). All enrolled subjects will receive 100 mg of aspirin plus 75 mg of clopidogrel for at least 5 days before SAC. One day prior to SAC, the aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU) will be measured using VerifyNow (Accumetrics, San Diego, California). Previous studies found that thromboembolic events during the periprocedural and follow-up periods were more likely to occur in patients with low responsiveness to antiplatelet therapy, so this study will include only patients with an adequate response to antiplatelet agents.\(^{3,6,18}\).
In this study, in reference to several studies, the appropriate range of response to antiplatelet agents will be determined as ARU < 550 and PRU 85-219, considering the hemorrhagic and thromboembolic risks. Detailed inclusion and exclusion criteria of this study are described in Table 1. This study will be performed after approval from the institutional review board at each participating institution. Each subject will be asked to provide written informed consent prior to undergoing SAC for UIAs.

**Randomization**

After confirming that the subject meets all study eligibility criteria and signing the informed consent, each subject will be randomized in a 1:1 fashion to a short-term or long-term dual antiplatelet therapy group using a computer-generated randomized sequence. Central randomization will be performed, and a random number will be given by trial online process registration. Allocation will be known to all involved in this study.

**Treatment**

The SAC procedures will be performed under general or local anesthesia according to the protocol of each institution. Systemic heparinization will be performed after the femoral introducer sheath is placed, and heparin will be later infused at an hourly booster dose of 1000 IU with monitoring of the activated clotting time. Rotational angiography for three-dimensional (3D) image reconstruction will be performed before SAC. Based on the 3D images, at least two working projections that provide the best image of the aneurysmal neck will be determined.

After placing a microcatheter into the aneurysmal sac for coil delivery, the stent will be deployed using another microcatheter to sufficiently cover the aneurysmal neck. Like this, the jailing technique will be given priority for SAC, but a trans-stenting technique will also be allowed depending on the situation. Selection of detachable bare platinum coils, type of stents, length of stents and diameter of
stents will be determined by the endovascular neurosurgeons at each participating institution. The aneurysm will be packed using bare metal coils until proper occlusion will be achieved or further coiling will be deemed dangerous. Finally, the procedure will be terminated after confirming the aneurysmal occlusion grade in DSA and detecting any procedural complications.

For subjects assigned to the short-term dual antiplatelet group, aspirin at a dose of 100 mg once daily plus clopidogrel at a dose of 75 mg once daily will be prescribed for 6 months after the procedure; after 6 months, this therapy will be exchanged for daily oral treatment with 100 mg of aspirin. For subjects assigned to the long-term dual antiplatelet group, aspirin at a dose of 100 mg once daily plus clopidogrel at a dose of 75 mg once daily will be prescribed for 12 months after the procedure; after 12 months, this therapy will be exchanged for aspirin at a dose of 100 mg once daily.

Primary and secondary endpoints

The primary endpoint will be delayed thromboembolic events, which are defined as a transient ischemic attack or ischemic stroke with evidence of infarction on diffusion weighted imaging, which occur in a vascular territory consistent with the stented vessel location between 1 month and 18 months after SAC. The secondary endpoint of the study will include the following: (1) bleeding events according to current updated thrombolysis in myocardial infarction (TIMI) bleeding criteria between 1 month and 18 months after SAC \(^{10}\), (2) periprocedural complications including thromboembolic and hemorrhagic events within 1 month after SAC, (3) neurological outcomes as measured by the modified Rankin Scale (mRS) scores at inclusion in the study and at 1, 6, 12 and 18 months after SAC, (4) ARU and PRU at 6 months after SAC, (5) aneurysm obliteration grades as described by the Roy-Raymond occlusion classification at immediate procedure and at 18 months after SAC \(^{13}\), and (6) morbidity and mortality between the 1- and 18-month follow-up after SAC. Table 2 shows the schedule of study visits.
Data safety monitoring board

The data safety monitoring board (DSMB) will be composed of three research-related neurosurgeons including the principal investigator, one contract research organization staff member, and three non-research-related neurosurgeons. The DSMB will review the data and monitor the safety while maintaining the scientific integrity of the trial. Based on the safety data, the DSMB will determine the reporting practice and recommend modifications to the protocol, suspension or termination of the trial.

Sample size

Recent studies showed that delayed thromboembolic complication rates ranged from 3.5% to 7.9%\(^2,7,15\). Based on the results of these studies, the rate of delayed thromboembolic complications was estimated to be 5.4% in the short-term dual antiplatelet therapy group within 18 months after SAC. Assuming that a delayed thromboembolic complication rate would be reduced to 1% in the long-term dual antiplatelet therapy group after SAC (rate difference, 4.4%), taking into account a two-sided significance level of 0.05 with 80% power, the calculated sample size would be 250 subjects per group. Considering a 5% loss to follow-up, this study will require 528 subjects (264 subjects in each group).

Statistical analyses

An intention-to-treat analysis will be used in all analyses. Categorical data will be presented with numbers, including percentages, and continuous data will be presented with means, including standard deviations. The Wilcoxon rank sum test will be used for continuous variables, and chi-square or Fisher’s exact tests will be used for nominal factors in comparisons of baseline characteristics. The percentage of subjects with delayed thromboembolic events between 1 and 18 months after SAC will be calculated in each of the 2 groups. The cumulative rate of the primary endpoint in each of the 2
groups will be analyzed by using Kaplan-Meier estimates. Cox proportional hazard analysis will be used to analyze the primary outcome, adjusted for covariables with 95% confidence intervals. For the secondary endpoint of binary data and, as measured at a single endpoint, Cox proportional hazard analysis will be used, adjusted covariables with 95% confidence intervals. Subgroup analysis will be performed to evaluate treatment effect modification. The primary outcome will be compared in the predefined subgroups, predefined by aneurysm size (≤10 mm or > 10 mm), aneurysm neck size (≤4 mm or >4 mm), stent type (laser-cut versus braided), stent length (≤20 mm or >20 mm), and aneurysm obliteration grade at 18 months (Roy-Raymond occlusion classification of 1 or ≥2). The significance of possible differences between subgroups in treatment effectiveness will be evaluated with the interaction terms.

RESULTS

The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up.

DISCUSSION

The aim of this study is to provide definitive information on the effect and safety of long-term dual antiplatelet therapy in comparison to short-term dual antiplatelet therapy in patients with UIAs after undergoing SAC.

Previously, several studies have published delayed thromboembolic complications according to the duration of dual antiplatelet therapy. In particular, Hwang et al. analyzed 403 aneurysms in 395
patients treated with SAC and reported that long-term use of dual antiplatelet therapy reduced the delayed thromboembolic event rate without increasing bleeding risk. However, these studies were retrospective, single-center studies. To date, no prospective and randomized comparative study to determine the optimal duration of dual antiplatelet therapy in patients with UIAs after undergoing SAC has been conducted. Also, guidelines for the optimal duration of dual antiplatelet therapy after SAC has not been established. This study is the first prospective, randomized and multicenter trial to conduct a direct comparison of long-term dual antiplatelet therapy versus short-term dual antiplatelet therapy in patients with UIAs after undergoing SAC. The randomized design of this study has a minimal risk of bias regarding the selection of patients for the long-term and short-term dual antiplatelet therapy groups. In addition, this study minimizes bias by excluding patients who, after undergoing platelet function test before SAC, are at high risk of thromboembolic or hemorrhagic complications during or after the procedure (ARU ≥ 550, PRU < 85, and PRU ≥ 220).

CONCLUSION

This paper details the design and aim of a prospective, randomized and multicenter trial that will determine the optimal duration of dual antiplatelet therapy in patients with UIAs after undergoing SAC. This study will provide evidence and novel insight into the optimal dual antiplatelet therapy duration for UIA patients undergoing SAC.

AUTHORS’ DECLARATION

Conflicts of interest
No potential conflict of interest relevant to this article was reported.

Informed consent

Informed consent was obtained from all individual participants included in this study.

Author contributions

Conceptualization: SBP, OKK, JHC; Data curation: SBP, OKK; Formal analysis: SBP, OKK;
Funding acquisition: OKK, JHC; Methodology: SBP, OKK, JHC; Project administration: SBP, OKK, YDK, BTK, JSO, KMK, CHK, CHK, JHC, YWK, YCL, HSB, SQP, JHC, KYP, JCP, HJK;
Visualization: SBP, OKK; Writing – original draft: SBP; Writing – review & editing: OKK, JHC

ORCID

Seung Pil Ban https://orcid.org/0000-0002-7774-0467

O-Ki Kwon https://orcid.org/0000-0002-7379-9891

Young Deok Kim https://orcid.org/0000-0002-1003-2677

Bum-Tae Kim https://orcid.org/0000-0003-2646-8165

Jae Sang Oh https://orcid.org/0000-0003-4570-6763

Kang Min Kim https://orcid.org/0000-0002-7409-4412

Chang Hyeun Kim https://orcid.org/0000-0001-6128-456X

Chang-Hyun Kim https://orcid.org/0000-0001-5401-5660
• Acknowledgements

Trial Registration: Clinical Research Information Service Identifier (KCT0006651) / ClinicalTrials. Gov Identifier (NCT05257824).

References


Unruptured intracranial aneurysm patients requiring stent-assisted coil embolization

Dual antiplatelet preparation (100mg of aspirin and 75mg of clopidogrel) for at least 5 days

Subject eligibility according to inclusion and exclusion criteria

Randomly assigned in a 1:1 ratio

Short-term duration
6 months dual antiplatelet therapy

Long-term duration
12 months dual antiplatelet therapy

Outcome evaluation between 1 month and 18 months

Fig. 1. Study flowchart.
Table 1. Inclusion and exclusion criteria

**Inclusion criteria**

- subjects over 19 years old
- subjects with mRS scores \( \leq 2 \)
- subjects with unruptured intracranial aneurysms
- subjects with appropriated aspirin and P2Y12 reaction units after dual antiplatelet preparation (100 mg of aspirin and 75 mg of clopidogrel) for at least 5 days prior to procedure [measured using VerifyNow]*
  - aspirin reaction unit \(< 550\)
  - P2Y12 reaction unit: 85-219
- subjects who agreed to this study (with informed consent)

**Exclusion criteria**

- subjects with neurological deficits (mRS \( \geq 3 \))
- subjects with an allergic reaction to antiplatelets (aspirin and clopidogrel) or contrast
- subjects with a high risk of hemorrhage such ICH or severe gastric ulceration
- subjects with coagulopathy
- subjects with thrombocytopenia (\(<100,000/mm^3\))
• subjects with liver diseases (>100IU/L of aspartate aminotransferase or alanine aminotransferase)
• subjects with renal diseases (>2 mg/dL of serum creatinine)
• subjects with underlying diseases that need to maintain dual antiplatelet drugs or anticoagulants.
• subjects with a high risk of strokes (atrial fibrillation, over 70% cerebral artery stenosis or cerebral artery occlusion, moyamoya disease, vascular malformations)
• subjects with uncontrolled congestive heart failure or angina
• subjects with malignant tumors
• subjects with a positive pregnancy test (serum or urine)
• subjects who are unconscious at the time of diagnosis.
• subjects who are unable to complete the required follow-up
• subjects with life-threatening diseases
• subjects with medical conditions with a life expectancy of less than two years
• subjects who are determined to be disqualified by researchers

mRS: modified Rankin scale, ICH: intracerebral hemorrhage

* VerifyNow (Accumetrics, San Diego, California).
<table>
<thead>
<tr>
<th>Visits</th>
<th>Inclusion visit</th>
<th>Procedure and hospitalization</th>
<th>Follow-up visit at 1 month</th>
<th>Follow-up visit at 6 months</th>
<th>Follow-up visit at 12 months</th>
<th>Follow-up visit at 18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>V0*</td>
<td></td>
<td></td>
<td>V2</td>
<td>V3</td>
<td>V4</td>
<td>V5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time in relation to the intervention</th>
<th>Within 3 months prior to V1</th>
<th>Day 0</th>
<th>Month 1 ± 2 weeks</th>
<th>Month 6 ± 4 weeks</th>
<th>Month 12 ± 4 weeks</th>
<th>Month 18 ± 4 weeks</th>
</tr>
</thead>
</table>

<p>| Informed consent | ●                           |
| Collection of demographic information | ●                           |
| Past medical history/family history | ●                           |
| Vital signs | ● ● ● ● ● ● ● ● |</p>
<table>
<thead>
<tr>
<th>Procedure/Checkup</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrocardiogram</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet drug response</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria confirmation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endovascular treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiologic evaluation‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant drug check</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
* V0 and V1 can coincide if a participant meets the inclusion/exclusion criteria

† Randomization of eligible participants may occur at any time between V0 and V1.

‡ Radiologic evaluation (skull X ray, MR angiography, CT angiography and TFCA) will be determined according to the endovascular neurosurgeons at each participating institution. MR angiography or TFCA must be required for V5.